Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection

Molecular Metabolism

Volumn 3, Issue 5, 2014, Pages 507-517

  Ussher, John R ^a   Baggio, Laurie L ^a   Campbell, Jonathan E ^a   Mulvihill, Erin E ^a   Kim, Minsuk ^a   Kabir, M Golam ^a   Cao, Xiemin ^a   Baranek, Benjamin M ^a   Stoffers, Doris A ^b   Seeley, Randy J ^c   Drucker, Daniel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Glucagon like peptide 1; Glucagon like peptide 1 receptor; Heart failure; Incretin; Ischemia; Myocardial infarction

Indexed keywords

DOXORUBICIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CCL2 GENE; CELL DISRUPTION; CHRONOTROPISM; CORONARY ARTERY LIGATION; CORONARY ARTERY OCCLUSION; GDF5 GENE; GENE; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GLP1R GENE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HEART ATRIUM ENLARGEMENT; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HEART RATE; HEART VENTRICLE REMODELING; HMOX1 GENE; MALE; MORTALITY; MOUSE; NONHUMAN; NPPA GENE; NPPB GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TGFB2 GENE; TNFA GENE; TREATMENT DURATION;

MUS;

EID: 84904283347     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.04.009     Document Type: Article

References (52)

1. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine 2008, 358(24):2545-2559.
2. Lindenfeld J., Masoudi F.A. Fluid retention with thiazolidinediones: does the mechanism influence the outcome?. Journal of the American College of Cardiology 2007, 49(16):1705-1707.
3. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine 2013, 369(14):1317-1326.
4. Nikolaidis L.A., Mankad S., Sokos G.G., Miske G., Shah A., Elahi D., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109(8):962-965.
5. Woo J.S., Kim W., Ha S.J., Kim J.B., Kim S.J., Kim W.S., et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arteriosclerosis, Thrombosis, and Vascular Biology 2013, 33(9):2252-2260.
6. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. Journal of Cardiac Failure 2006, 12(9):694-699.
7. Lonborg J., Vejlstrup N., Kelbaek H., Botker H.E., Kim W.Y., Mathiasen A.B., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. European Heart Journal 2012, 33(12):1491-1499.
8. Ussher J.R., Drucker D.J. Cardiovascular biology of the incretin system. Endocrine Reviews 2012, 33(2):187-215.
9. Sivertsen J., Rosenmeier J., Holst J.J., Vilsboll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nature Reviews Cardiology 2012, 9(4):209-222.
10. Kim M., Platt M., Shibasaki T., Quaggin S., Backx P.H., Seino S., et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nature Medicine 2013, 19(5):567-575.
11. Scrocchi L.A., Brown T.J., MacLusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nature Medicine 1996, 21254-21258.
12. Wilson-Pérez H.E., Chambers A.P., Ryan K.K., Li B., Sandoval D.A., Stoffers D., et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide-1 receptor deficiency. Diabetes 2013, 62(7):2380-2385.
13. Koitabashi N., Bedja D., Zaiman A.L., Pinto Y.M., Zhang M., Gabrielson K.L., et al. Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circulation Research 2009, 105(1):12-15.
14. Noyan-Ashraf M.H., Momen M.A., Ban K., Sadi A.M., Zhou Y.Q., Riazi A.M., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58(4):975-983.
15. Neilan T.G., Blake S.L., Ichinose F., Raher M.J., Buys E.S., Jassal D.S., et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007, 116(5):506-514.
16. Sauve M., Ban K., Momen A., Zhou Y.-Q., Henkelman R.M., Husain M., et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice. Diabetes 2010, 59(4):1063-1073.
17. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408.
18. Ussher J.R., Folmes C.D., Keung W., Fillmore N., Jaswal J.S., Cadete V.J., et al. Inhibition of serine palmitoyl transferase I reduces cardiac ceramide levels and increases glycolysis rates following diet-induced insulin resistance. PLoS One 2012, 7(5):e37703.
19. Gros R., You X., Baggio L.L., Kabir M.G., Sadi A.M., Mungrue I.N., et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003, 144(6):2242-2252.
20. Poornima I., Brown S.B., Bhashyam S., Parikh P., Bolukoglu H., Shannon R.P. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circulation Heart Failure 2008, 1(3):153-160.
21. Liu Q., Anderson C., Broyde A., Polizzi C., Fernandez R., Baron A., et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovascular Diabetology 2010, 9:76.
22. Bernink F.J., Timmers L., Diamant M., Scholte M., Beek A.M., Kamp O., et al. Effect of additional treatment with EXenatide in patients with an acute myocardial infarction: the EXAMI study. International Journal of Cardiology 2013, 167(1):289-290.
23. Vyas A.K., Yang K.C., Woo D., Tzekov A., Kovacs A., Jay P.Y., et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One 2011, 6(2):e17178.
24. Nathanson D., Ullman B., Lofstrom U., Hedman A., Frick M., Sjoholm A., et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 2012, 55(4):926-935.
25. Pederson R.A., Satkunarajah M., McIntosh C.H., Scrocchi L.A., Flamez D., Schuit F., et al. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor-/- mice. Diabetes 1998, 47(7):1046-1052.
26. Hansotia T., Maida A., Flock G., Yamada Y., Tsukiyama K., Seino Y., et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. Journal of Clinical Investigation 2007, 117(1):143-152.
27. Ayala J.E., Bracy D.P., James F.D., Burmeister M.A., Wasserman D.H., Drucker D.J. Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology 2010, 151(10):4678-4687.
28. Wohlfart P., Linz W., Hubschle T., Linz D., Huber J., Hess S., et al. Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. Journal of Translational Medicine 2013, 11:84.
29. Pyke C., Heller R.S., Kirk R.K., Orskov C., Reedtz-Runge S., Kaastrup P., et al. GLP-1 receptor localization in monkey and human tissue; novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014, 155(4):1280-1290.
30. Fagan T.C., Sawyer P.R., Gourley L.A., Lee J.T., Gaffney T.E. Postprandial alterations in hemodynamics and blood pressure in normal subjects. American Journal of Cardiology 1986, 58(7):636-641.
31. Ban K., Kim H., Cho J., Diamandis E., Backx P.H., Drucker D.J., et al. GLP-1(9-36) protects cardiomyocytes and endothelial cells from ischemia-reperfusion injury via cytoprotective pathways independent of the GLP-1 receptor. Endocrinology 2010, 151(4):1520-1531.
32. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117(18):2340-2350.
33. Noyan-Ashraf M.H., Shikatani E.A., Schuiki I., Mukovozov I., Wu J., Li R.K., et al. Aglucagon-like peptide-1 analogue reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 2013, 127(1):74-85.
34. Timmers L., Henriques J.P., de Kleijn D.P., Devries J.H., Kemperman H., Steendijk P., et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. Journal of the American College of Cardiology 2009, 53(6):501-510.
35. Nikolaidis L.A., Elahi D., Shen Y.T., Shannon R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. American Journal of Physiology. Heart and Circulatory Physiology 2005, 289(6):H2401-H2408.
36. Abu-Hamdah R., Rabiee A., Meneilly G.S., Shannon R.P., Andersen D.K., Elahi D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. Journal of Clinical Endocrinology and Metabolism 2009, 94(6):1843-1852.
37. Tatarkiewicz K., Sablan E.J., Polizzi C.J., Villescaz C., Parkes D.G. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2014, 306(7):R490-R498.
38. Richards P., Parker H.E., Adriaenssens A.E., Hodgson J.M., Cork S.C., Trapp S., et al. Identification and characterisation of glucagon-like peptide-1 receptor expressing cells using a new transgenic mouse model. Diabetes 2014, 63(4):1224-1233.
39. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110(8):955-961.
40. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide-1 (GLP-1) can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54(1):146-151.
41. Kitakaze M., Asakura M., Kim J., Shintani Y., Asanuma H., Hamasaki T., et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007, 370(9597):1483-1493.
42. Bao W., Aravindhan K., Alsaid H., Chendrimada T., Szapacs M., Citerone D.R., et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One 2011, 6(8):e23570.
43. Bugger H., Abel E.D. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014, 57(4):660-671.
44. Lønborg J., Vejlstrup N., Kelbæk H., Nepper-Christensen L., Jørgensen E., Helqvist S., et al. Impact of acute hyperglycemia on myocardial infarct size, area at risk and salvage in patients with ST elevation myocardial infarction and the association with exenatide treatment - results from a randomized study. Diabetes 2014, 10.2337/db13-1849.
45. Lamont B.J., Li Y., Kwan E., Brown T.J., Gaisano H., Drucker D.J. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. Journal of Clinical Investigation 2012, 122(1):388-402.
46. Campbell J.E., Drucker D.J. Pharmacology physiology and mechanisms of incretin hormone action. Cell Metabolism 2013, 17(4):819-837.
47. Chai W., Dong Z., Wang N., Wang W., Tao L., Cao W., et al. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 2012, 61(4):888-896.
48. Subaran S.C., Sauder M.A., Chai W., Jahn L.A., Fowler D.E., Aylor K.W., et al. GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clinical Science (London) 2014, 127(3):163-170.
49. Dokken B.B., Hilwig W.R., Teachey M.K., Panchal R.A., Hubner K., Allen D., et al. Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction. Resuscitation 2010, 81(6):755-760.
50. Gejl M., Sondergaard H.M., Stecher C., Bibby B.M., Moller N., Botker H.E., et al. Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2012, 97(7):E1165-E1169.
51. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. Journal of Clinical Investigation 2002, 110(1):43-52.
52. Griffioen K.J., Wan R., Okun E., Wang X., Lovett-Barr M.R., Li Y., et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovascular Research 2011, 89(1):72-78.